MONTGOMERYVILLE, Pa. TEL AVIV, Israel, May 01, 2012 (BUSINESS WIRE) —
PhotoMedex, Inc. (nasdaqgs:PHMD) today announced that its application
for registration of shares of its common stock for dual listing on the
Tel-Aviv Stock Exchange (the “TASE”) has been accepted and will commence
trading on the TASE on May 3, 2012 under the ticker symbol PHMD.TA. The
Company’s common stock will continue to be listed on the NASDAQ Global
Select Market in the United States under the ticker symbol PHMD and will
remain subject to the rules and regulations of NASDAQ and the U.S.
Securities and Exchange Commission.

“We congratulate and welcome PhotoMedex to the Tel-Aviv Stock Exchange,”
said Ester Levanon, CEO of the TASE. “The TASE is the home of Israel’s
innovative and growing companies and with PhotoMedex’s significant
market value it will be part of the TASE’s major indices. We are
committed to the TASE being a leading and sophisticated stock exchange,
especially in the technology and biotechnology areas by bringing
significant companies like PhotoMedex to the local market. We encourage
Israeli oriented companies traded abroad to dual list on the TASE and
believe that it provides many benefits, including exposure to more
investors, extended trading hours, investments by specialized ETFs and
mutual funds as well as access of local institutional and private
investors to global growing companies such as PhotoMedex. ”

Dr. Dolev Rafaeli, chief executive officer of PhotoMedex, said, “We are
very happy to join the TASE with a dual listing as PhotoMedex has a
strong connection to the Israeli community with offices in Hod Hasharon.
We view our listing on the TASE as a logical extension of our strong
presence in Israel and our connection to its vibrant medical technology
sector.”

TASE links to the U.S. markets with a direct link to DTC, a subsidiary
of the Depository Trust and Clearing Corporation, which facilitates the
trading of dual-listed securities.

About PhotoMedex

PhotoMedex is a global skin health company providing integrated disease
management and aesthetic solutions to dermatologists, professional
aestheticians and consumers. The company provides proprietary products
and services that address skin diseases and conditions including
psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain
types of skin cancer) and photo damage. Its experience in the physician
market provides the platform to expand its skin health solutions to spa
markets, as well as traditional retail, online and infomercial outlets
for home-use products. As a result of its December 2011 merger with
Radiancy Inc., PhotoMedex has added a range of home-use devices under
the no!no!(TM) brand, for various indications including hair removal, acne
treatment and skin rejuvenation. The company also offers a professional
product line for acne clearance, skin tightening, psoriasis care and
hair removal sold to physician clinics and spas.

Safe Harbor

Investors are cautioned that statements in this press release constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks related to the satisfaction of
customary listing conditions related to the dual listing. There can be
no assurance that PhotoMedex will be able to complete or maintain the
dual listing requirements. Actual results may differ materially from the
results anticipated in these forward-looking statements. Additional
information on potential factors that could affect our results and other
risks and uncertainties are detailed in PhotoMedex’s periodic reports,
including its Annual Report on Form 10-K for the year ended December 31,
2011, and are available on the SEC’s web site at
www.sec.gov .

SOURCE: PhotoMedex, Inc.

        
        LHA 
        Kim Sutton Golodetz (investors), 212-838-3777 
        Kgolodetz@lhai.com 
        or 
        Bruce Voss, 310-691-7100 
        Bvoss@lhai.com 
        @LHA_IR_PR 
        or 
        PhotoMedex, Inc. 
        Dennis McGrath, 215-619-3287 
        President  CFO 
        info@photomedex.com
        

Copyright Business Wire 2012